Neuroprotective effect of cyclosporine and FK506 against 3-nitropropionic acid induced cognitive dysfunction and glutathione redox in rat: Possible role of nitric oxide

Neuroscience Research

Volumn 63, Issue 4, 2009, Pages 302-314

  Kumar, Puneet ^a   Kumar, Anil ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

3 Nitropropionic acid; FK 506; Glutathione; Huntington's disease; Immunophilins; Nitric oxide

Indexed keywords

3 NITROPROPIONIC ACID; ACETYLCHOLINESTERASE; ARGININE; CYCLOSPORIN; GLUTATHIONE; GLUTATHIONE DISULFIDE; GLUTATHIONE TRANSFERASE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVITY; HIPPOCAMPUS; MALE; MEMORY; NEUROPROTECTION; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT;

ACETYLCHOLINESTERASE; ANALYSIS OF VARIANCE; ANIMALS; ARGININE; BEHAVIOR, ANIMAL; BRAIN; COGNITION DISORDERS; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; GLUTATHIONE; GLUTATHIONE TRANSFERASE; MALE; MAZE LEARNING; NEUROPROTECTIVE AGENTS; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRO COMPOUNDS; OXIDATIVE STRESS; PROPIONIC ACIDS; RATS; RATS, WISTAR; TACROLIMUS; TIME FACTORS;

EID: 61649127498     PISSN: 01680102     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neures.2009.01.005     Document Type: Article

References (55)

1. Akula K.K., Dhir A., and Kulkarni S.K. Nitric oxide signaling pathway in the anti-convulsant effect of adenosine against pentylenetetrazol-induced seizure threshold in mice. Eur. J. Pharmacol. 587 (2008) 129-134
2. Avramut M., and Achim C.L. Immunophilins in nervous system degeneration and regeneration. Curr. Top. Med. Chem. 3 (2003) 1376-1382
3. Beckman J.S. Oxidative damage and tyrosine nitration from peroxynitrite. Chem. Res. Toxicol. 9 (1996) 836-844
4. Bożena G., Tomasz T., and Andrzej M. Immunosuppressive immunophilin ligands attenuate damage in cultured rat astrocytes depleted of glutathione and exposed to simulated ischemia in vitro comparison with N-acetylcysteine. NeuroToxicology 26 (2005) 373-384
5. Cipriani S., Bizzoco E., Gianfriddo M., Melani A., Vannucchi M.G., and Pedata F. Adenosine A2A receptor antagonism increases nNOS-immunoreactive neurons in the striatum of Huntington transgenic mice. Exp. Neurol. 213 (2008) 163-170
6. Conde M., Andrade J., Bedoya F.J., Santa M.C., and Sobrino F. Inhibitory effect of cyclosporin A and FK506 on nitric oxide production by cultured macrophages. Evidence of a direct effect of nitric oxide synthase activity. Immunology 84 (1995) 476-481
7. Cooper D.B., Ales G., Lange C., and Clement P. Atypical onset of symptoms in Huntington disease: severe cognitive decline preceding chorea or other motor manifestations. Cogn. Behav. Neurol. 19 (2006) 222-224
8. Cruz R., Almaguer M.W., and Bergado Rosado J.A. Glutathione in cognitive function and neurodegeneration. Rev. Neurol. 36 (2003) 877-886
9. Cruz-Aguado R., Almaguer-Melian W., Díaz C.M., Lorigados L., and Bergado J. Behavioral and biochemical effects of glutathione depletion in the rat brain. Brain Res. Bull. 55 (2001) 327-333
10. Dawson T., Steiner J.P., Dawson V.L., Dinerman J.L., Uhl G.R., and Snyder S.H. Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 9808-9812
11. Deshpande S.B., Hida H., Takei-Io N., Masuda T., Baba H., and Nishino H. Involvement of nitric oxide in 3-nitropropionic acid-induced striatal toxicity in rats. Brain Res. 1108 (2006) 205-215
12. Dineley K.T., Hogan D., Zhang W.R., and Taglialatela G. Acute inhibition of calcineurin restores associative learning and memory in Tg2576 APP transgenic mice. Neurobiol. Learn. Mem. 88 (2007) 217-224
13. Duckworth E.A., Koutouzis T.K., Borlongan C.V., Gordon M.N., Willing A.E., Cahill D.W., and Sanberg P.R. Rats receiving systemic 3-nitropropionic acid demonstrate impairment of memory in Morris water maze. Psychobiology 27 (1999) 561-566
14. Dusting G.J., Kazuhiro A., Haruyo H., Melanie S., and Vladimir G. Cyclosporin A and tacrolimus (FK506) suppress expression of inducible nitric oxide synthase in vitro by different mechanisms. Br. J. Pharmacol. 128 (1999) 337-344
15. Edkins R.D., Rybak L.P., and Hoffman D.W. Comparison of cyclosporine and FK506 effects on glutathione levels in rat cochlea, brain, liver and kidney. Biochem. Pharmacol. 43 (1992) 911-913
16. Ellman G.L., Courtney K.D., Andres V., and Featherston R.M.A. New and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7 (1961) 88-91
17. Ellman G.L. Tissue sulfhydryl groups. Arch. Biochem. Biophys. 82 (1959) 70-77
18. Frautschy S.A., Hu W., Kim P., Miller S.A., White-Harris M.E., Chu T., and Cole G.M. Phenolic anti-inflammatory antioxidant reversal of Aβ-induced cognitive deficits and neuropathology. Neurobiol. Aging 22 (2001) 993-1005
19. Gil J.M., and Rego A.C. Mechanisms of neurodegeneration in Huntington's disease. Eur. J. Neurosci. 27 (2008) 2803-2820
20. Gornall A.G., Bardawill C.J., and David M.M. Determination of serum proteins by means of the biuret reaction. J. Biol. Chem. 177 (1949) 751-766
21. Habig W.H., Pabst M.J., and Jakoby W.S. Glutathione-S-transferase: the first enzymatic step in mercapturic acid formation. J. Biol. Chem. 249 (1974) 7130-7139
22. Hattori Y., and Nakanishi N. Effects of cyclosporin A and FK506 on nitric oxide and tetrahydrobiopterin sysnthesis in bacterial lipopolysaccharide-treated J774 macrophages. Cell Immunol. 165 (1995) 7-11
23. Hernández-Espinosa D., and Morton A.J. Calcineurin inhibitors cause an acceleration of the neurological phenotype in a mouse transgenic for the human Huntington's disease mutation. Brain Res. Bull. 69 (2006) 669-679
24. Homayoun H., Khavandgar S., Mehr S.E., Namiranian K., and Dehpour A.R. The effects of FK506 on the development and expression of morphine tolerance and dependence in mice. Behav. Pharmacol. 14 (2003) 121-127
25. Hoth K.F., Paulsen J.S., Moser D.J., Tranel D., Clark L.A., and Bechara A. Patients with Huntington's disease have impaired awareness of cognitive, emotional, and functional abilities. J. Clin. Exp. Neuropsychol. 29 (2007) 365-376
26. Huang L.S., Sun G., Cobessi D., Wang A.C., Shen J.T., Tung E.Y., Anderson V.E., and Berry E.A. 3-Nitropropionic acid is a suicide inhibitor of mitochondrial respiration that, upon oxidation by complex II, forms a covalent adduct with a catalytic base arginine in the active site of the enzyme. J. Biol. Chem. 281 (2006) 5672-5965
27. Juan P., Bolaños A.A., Victoria S., Stephan P., John M.L., John B.C., and Simon J.R.H. Nitric oxide-mediated mitochondrial damage in the brain: mechanisms and implications for neurodegenerative diseases. J. Neurochem. 68 (2002) 2227-2240
28. Kaminska B., Gaweda-Walerych K., and Zawadzka M. Molecular mechanisms of neuroprotective action of immunosuppressants-facts and hypotheses. J. Cell Mol. Med. 8 (2004) 45-58
29. Karanian D.A., Baude A.S., Brown Q.B., Parsons C.G., and Bahr B.A. 3-Nitropropionic acid toxicity in hippocampus: protection through N-methyl-d-aspartate receptor antagonism. Hippocampus 16 (2006) 834-842
30. Knott A.B., and Bossy-Wetzel E. Nitric oxide in health and disease of the nervous system. Antioxid. & Redox. Signal 11 (2009) 541-554
31. Kumar P., Padi S.S., Naidu P.S., and Kumar A. Possible neuroprotective mechanisms of Curcumin in attenuating 3-nitropropionic acid-induced neurotoxicity. Methods Finding Exp. Clin. Pharmacol. 29 (2007) 1-7
32. Kumar P., Padi S.S., Naidu P.S., and Kumar A. Effect of resveratrol on 3-nitropropionic acid-induced biochemical and behavioural changes: possible neuroprotective mechanisms. Behav. Pharmacol. 17 (2006) 485-492
33. Leventhal L., Sortwell C.E., Hanbury R., Collier T.J., Kordower J.H., and Palfi S. Cyclosporin A protects striatal neurons in vitro and in vivo from 3-nitropropionic acid toxicity. J. Comp. Neurol. 425 (2000) 471-478
34. Liu X., Luo X., and Hu W. Studies on the epidemiology and etiology of moldy sugarcane poisoning in China. Biomed. Environ. Sci. 5 (1992) 161-177
35. Liu J. FK506 and cyclosporin: molecular probes for studying intracellular signal transduction. Trends Pharmacol. Sci. 14 (1993) 182-188
36. Maher P. The effects of stress and aging on glutathione metabolism. Ageing Res. Rev. 4 (2005) 288-314
37. Maňákováa S., Singh A., Kääriäinena T., Taaria H., Kulkarni S.K., and Männistöc P.T. Failure of FK506 (tacrolimus) to alleviate apomorphine-induced circling in rat Parkinson model in spite of some cytoprotective effects in SH-SY5Y dopaminergic cells. Brain Res. 1038 (2005) 83-91
38. Mao Z., Choo Y.S., and Lesort M. Cystamine and cysteamine prevent 3-NP-induced mitochondrial depolarization of Huntington's disease knock-in striatal cells. Eur. J. Neurosci. 23 (2006) 1701-1710
39. Montoya A., Pelletier M., Menear M., Duplessis E., Richer F., and Lepage M. Episodic memory impairment in Huntington's disease: a meta-analysis. Neuropsychologia 44 (2006) 1984-1994
40. Montoya A., Price B.H., Menear M., and Lepage M. Brain imaging and cognitive dysfunctions in Huntington's disease. J. Psychiatr. Neurosci. 31 (2006) 21-29
41. Morita M., Imai H., Liu Y., Xu X., Sadamatsu M., Nakagami R., Shirakawa T., Nakano K., Kita Y., Yoshida K., Tsunashima K., and Kato N. FK506-protective effects against trimethyltin neurotoxicity in rats: hippocampal expression analyses reveal the involvement of periarterial osteopontin. Neuroscience 153 (2008) 1135-1145
42. Nishinaka Y., Sugiyama S., Yokota M., Saito H., and Ozawa T. Protective effect of FK506 on ischemia/reperfusion-induced myocardial damage in canine heart. J. Cardiovasc. Pharmacol. 21 (1993) 448-454
43. Pandey M., Varghese M., Sindhu K.M., Sreetama S., Navneet A.K., Mohanakumar K.P., and Usha R. Mitochondrial NAD+-linked State 3 respiration and complex-I activity are compromised in the cerebral cortex of 3-nitropropionic acid-induced rat model of Huntington's disease. J. Neurochem. 104 (2008) 420-434
44. Pelegrí C., Duran-Vilaregut J., Del V.J., Crespo-Biel N., Ferrer I., Pallàs M., Camins A., and Vilaplana J. Cell cycle activation in striatal neurons from Huntington's disease patients and rats treated with 3-nitropropionic acid. Int. J. Dev. Neurosci. 26 (2008) 665-671
45. Pong K., and Zaleska M.M. Therapeutic implications for immunophilin ligands in the treatment of neurodegenerative diseases. CNS Neurol. Disorders-Drug Targets 2 (2003) 349-356
46. Serrano J., Encinas J.M., Fernández A.P., Rodrigo J., and Martínez A. Effects of acute hypobaric hypoxia on the nitric oxide system of the rat cerebral cortex: protective role of nitric oxide inhibitors. Neuroscience 142 (2006) 799-808
47. Sharkey J., and Butcher S.P. Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischaemia. Nature 371 (1994) 336-339
48. Shear D.A., Haik K.L., and Dunbar G.L. Creatine reduces 3-nitropropionic-acid-induced cognitive and motor abnormalities in rats. Neuroreport 11 (2000) 1833-1837
49. Singh A., Naidu P.S., and Kulkarni S.K. Possible antioxidant and neuroprotective mechanisms of FK506 in attenuating haloperidol-induced orofacial dyskinesia. Eur. J. Pharmacol. 477 (2003) 87-94
50. Smith R., Chung H., Rundquist S., Maat-Schieman M.L., Colgan L., Englund E., Liu Y.J., Roos R.A., Faull R.L., Brundin P., and Li J.Y. Cholinergic neuronal defect without cell loss in Huntington's disease. Hum. Mol. Genet. 15 (2006) 3119-3131
51. Sugino T., Nozaki K., Takagi Y., Hattori I., Hashimoto N., and Yodoi J. Expression and distribution of redox regulatory protein, thioredoxin after metabolic impairment by 3-nitropropionic acid in rat brain. Neurosci. Lett. 275 (1999) 145-148
52. Udayabanu M., Kumaran D., Nair R.U., Srinivas P., Bhagat N., Aneja R., and Katyal A. Nitric oxide associated with iNOS expression inhibits acetylcholinesterase activity and induces memory impairment during acute hypobaric hypoxia. Brain Res. 1230 (2008) 138-149
53. Verny C., Allain P., Prudean A., Malinge M.C., Gohier B., Scherer C., Bonneau D., Dubas F., and Le Gall D. Cognitive changes in asymptomatic carriers of the Huntington disease mutation gene. Eur. J. Neurol. 14 (2007) 1344-1350
54. Villarán R.F., Tomás-Camardiel M., de Pablos R.M., Santiago M., Herrera A.J., Navarro A., Machado A., and Cano J. Endogenous dopamine enhances the neurotoxicity of 3-nitropropionic acid in the striatum through the increase of mitochondrial respiratory inhibition and free radicals production. Neurotoxicology 29 (2008) 244-258
55. Zahler W.L., and Cleland W.W. A specific and sensitive assay for disulfides. J. Biol. Chem. 243 (1968) 716-719